Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults

Obesity Clinical Trial

Official title:

Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults With Multiple Chronic Conditions: A Sequential, Multiple Assignment, Randomized Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06044571
• Other study ID #: 23-1146
• Secondary ID: 1R01AG077163-01A
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2024
• Est. completion date: September 1, 2027

Study information

• Verified date: January 2024
• Source: University of North Carolina, Chapel Hill
• Contact: Amy S Plymale, BS
• Phone: 919-962-3412
• Email: amynsp[@]email.unc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to answer the fundamental questions of which initial, first-line weight loss intervention should be offered to older adults with obesity and multiple chronic conditions and how to address the high non-response rates observed with most conventional strategies. A sequential, multiple assignment, randomized trial (SMART) design will permit the evaluation of treatment combinations that maximize weight loss and will provide data on constructing a future tailored, adaptive intervention. If successful, these findings will identify interventions that could markedly improve health and quality of life of these older adults, reduce long-term disability, and lower healthcare costs

Description:

Purpose: Consistent with the research priorities of the National Institute on Aging, this research protocol will investigate the optimal intervention sequence to achieve weight loss in older adults with obesity and more than 2 chronic conditions, termed multiple chronic conditions (MCC). To this end, the specific aims are to: 1) test the superiority of an initial prescriptive or behavioral intervention using an adaptive strategy for early non-responders; 2) assess the patterns of initial weight loss and compare strategies for non-responders using an adaptive strategy; and 3) examine the cost-effectiveness from a societal perspective for maintaining weight loss of the proposed sequences at 78 weeks (26 weeks post-intervention completion). Procedures (methods): The investigators will conduct a 52-week, two-stage, Sequential, Multiple Assignment, Randomized Trial (SMART) enrolling 180 older adults with obesity and MCC to compare two weight loss interventions: 1) a prescriptively-focused, medically-tailored, weight loss intervention(prescriptive), or 2) a behaviorally-focused, health coaching intervention (behavioral). Consistent with a SMART design, at 8 weeks, the investigators will randomize early non-responders (weight loss of < 2.5%) to (a) a combination of prescriptive and behavioral interventions; or (b) switching to either a prescriptive, medically-tailored model (or vice versa). Aim 1 - Efficacy Test the superiority of an initial prescriptive vs. behavioral intervention on the differences in weight loss (primary outcome) and secondary outcomes, using an adaptive strategy for early non-responders in a 52-week, telehealth-based SMART. At 52-weeks, percent weight loss (primary outcome) will be greater among patients initially randomized to a prescriptive intervention, as will global health and physical function, anthropometry, behavioral treatment targets and risk factors, and clinical indices (secondary outcomes). Aim 2 - Precision Medicine Assess the patterns of initial weight loss and compare strategies for non-responders to weight loss (combined prescriptive and behavioral, or switching initial treatment strategies [prescriptive to behavioral, or behavioral to prescriptive]). The investigators will estimate an adaptive strategy (dynamic treatment regime) to give the right intervention to the right participant. The investigators hypothesize that this dynamic regime will lead to a better outcome, on average, compared to the best non-adaptive (fixed) regime Aim 3 - Cost-Effectiveness Examine the cost-effectiveness from a societal perspective at 78-weeks (26 weeks post-intervention completion). For the initial, first-line interventions, the investigators will estimate the incremental cost per percent weight change and assess secondary outcomes of the incremental cost for maintaining at least a 5% weight loss, and quality-adjusted life years. The investigators will also model the cost-effectiveness of the precision medicine approach predicted to have the greatest individualized likelihood of weight loss response.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 180
• Est. completion date: September 1, 2027
• Est. primary completion date: September 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria based on chart review at the time of screening (within 8 weeks of

randomization):

• Community-dwelling adult living independently (not a resident of a nursing home or an assisted living);
• Aged 65-85 years 85 (unclear benefits of weight loss if >85 years)7-9
• Obesity (body mass index: =30 kg/m2);
• English-speaking; -=2 chronic medical conditions that require ongoing care (excluding dementia and osteoporosis as a chronic condition) - these are based on Medicare' MCC (e.g., alcohol abuse, arthritis (osteoarthritis, rheumatoid), asthma, atrial fibrillation, autism spectrum disorders, cancer (breast, colorectal, lung, prostate), chronic kidney disease, chronic obstructive pulmonary disease, depression, diabetes, drug/substance abuse, heart failure, hepatitis, Human Immunodeficiency Virus / Acquired Immunodeficiency Disease Syndrome, hyperlipidemia, hypertension, ischemic heart disease, schizophrenia/other psychotic disorders, stroke). We acknowledge that there are no fully defined definitions and hence we will be assessing MCC (or multimorbidity) in different manners;
• medical clearance by PCP (Primary Care Provider)
• Callahan cognitive screen = 3 correct items; items (a score of three or more correct items indicates an ability to consent);
• OARS (Older Americans Resources and Services)survey score of =12; (a score of 12 or more indicates no impairments or disability)
• Readiness to change score of =6/10; Exclusion Criteria: Any individual who meets one or more of the following criteria will be excluded from participation based on chart review at the time of screening (within 8 weeks of

randomization):

• documented diagnosis in the electronic health record of dementia of any type;
• documented diagnosis in the electronic health record of weight loss surgery in the past;
• untreated psychiatric disorder that would impair the ability to participate (bipolar, schizophrenia) based on medical record review;
• life-threatening illness;
• terminal illness (e.g., palliative care, hospice patient) based on medical record review whose life expectancy is <12 months as determined by a physician;
• nursing home or hospital admission in past three months;
• advanced comorbidities based on medical record review;
• heart - recent hospital admission for heart failure, myocardial infarction, stroke in past 3 months, unstable disease (new york class III or IV congestive heart failure);
• chronic renal failure - chronic kidney disease stage IV or V (e.g., GFR [glomerular filtration rate] <30ml/min);
• non-skin cancer - history of requiring active treatment in the past year;
• liver failure or cirrhosis;
• chronic obstructive pulmonary disease - on oxygen or requiring steroids;
• weight loss contraindication as noted by the PCP;
• instability of weight loss, which is greater than 5% weight loss in the past 12 weeks;
• anti-obesity medications including orlistat, semaglutide, liraglutide, tirzepetide, naltrexone-bupropion and phentermine prior to initiation of study procedures;
• current use of bone acting medications (e.g., raloxifene, calcitonin, parathyroid hormone during the past year, Parathyroid Hormone Analogues (PTH-analogues [e.g., teriparatide, abaloparatide], sclerostin) inhibitors (romosozumbab), RANK ligand inhibitors (denosumab) or bisphosphonates during the last two years;
• osteoporosis by medical record (t-score -2.5 and below on hip or spine scan) or history of fragility fractures;
• elective surgery in next 12 months;
• recent (<1 mo) COVID-19 infection;
• current or past participation (in the past 12 months) in another weight-loss study;
• Planning on moving out of the area in the next 18 months.

Related Conditions & MeSH terms

• Chronic Disease
• Disease
• Multiple Chronic Conditions
• Obesity
• Weight Loss

Intervention

Other:
• Prescriptive
Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).

Behavioral:
• Behavioral
Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.

Locations

Country	Name	City	State
United States	UNC Center for Aging and Health	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in weight from baseline	Absolute change in weight percentage (%) over time from baseline to 52-weeks. Weight will be objectively measured on a digital scale. A negative number will indicate weight loss.	8, 16, 26, 52, 78 weeks
Secondary	Change in Patient reported outcomes measurement information systems (PROMIS)- Global health	PROMIS (Patient Reported Outcomes Measurement Information System) gauges physical, mental, and social aspects of health (5-point scale). A mean standardized score for the population is 50; 10 points indicate one standard deviation. Higher scores indicate better health. Range (0-100)	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Patient reported outcomes measurement information systems (PROMIS)- Physical function	Self-reported physical function (5-point scale) measure that is a responsive measure evaluating mobility and activities of daily living; A mean standardized score for the population is 50; 10 points indicate one standard deviation. Higher scores indicate better health. Range (0-100)	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in 30-second sit-to-stand from baseline	This is a construct of physical function that predicts falls and disability and is sensitive to change. The 30-second sit-to-stand test is administered using a folding chair without arms and involves recording the number of stands from a seated position a person can complete in 30 seconds. Change in 30-s sit-to-stand in repetitions over time will be reported from baseline to 78-weeks. An improvement in repetitions will represent an improvement of physical function. The continuous value correlates with quadriceps Minimal Clinically Important Difference (2.0 repetitions)	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in grip strength from baseline	An objective measure that relates to upper and lower extremity strength, and predicts mobility disability. Using a Jamar dynamometer, change in participant's maximal grip strength measurement in kilograms from baseline. Absolute change in grip strength in kilograms over time will be reported from baseline to 78-weeks. An increase in kilograms represented on the device will represent an improvement of physical function. No cutoffs will be used for this - the research team will be use the continuous value.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in gait speed from baseline	Gait speed (measured in meters/second or m/s) measures how long it takes a person to travel a given distance. It is A simple, clinical measure of objective physical function that reflects health and functional status and predicts falls, disability, and mortality. Gait Speed is measured using the time in seconds it takes a participant to complete a 4 meter course while walking at a usual pace. Gait speed is measured as distance (meters) ÷ time (seconds). An absolute change in gait speed will be the difference from follow-up measures and baseline. An improvement in gait speed represents an improvement in physical function. Units are meters/second. Normal >1.2m/s.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in 6-minute walk from baseline	A measure of aerobic endurance (normal distance 400-700m) that is a surrogate for submaximal aerobic/cardiovascular fitness. Clinically significant change ranges between 14-30.5 m.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in waist circumference from baseline	Absolute change in waist circumference in centimeters (cm) over time from baseline. Waist circumference will be measured objectively using a tape measure. A negative number will indicate a loss in waist circumference	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in hip circumference from baseline	Absolute change in hip circumference in centimeters (cm) over time from baseline. Hip circumference will be measured objectively using a tape measure. A negative number will indicate a loss of hip circumference	0, 8, 16, 26, 52, 78 weeks
Secondary	Proportion with greater than or equal to 5% weight loss	The proportion achieving a clinically significant 5% weight loss	8, 16, 26, 52, 78 weeks
Secondary	Change in % body fat from baseline	Dual x-ray absorptiometry (General Electric Lunar iDXA) software will assess total body fat % (percent). A reduction in the percentage of total body fat is suggestive of improvements in health related outcomes.	0, 26, 52 weeks
Secondary	Change in volume of visceral fat from baseline	Dual x-ray absorptiometry (General Electric Lunar iDXA) software will assess visceral fat mass % (percent). A reduction in visceral fat volume is suggestive of improvements in health related outcomes.	0, 26, 52 weeks
Secondary	Change in appendicular lean mass from baseline	Dual x-ray absorptiometry (General Electric Lunar iDXA) software will assess percent (%) lean mass (total, segmental). A reduction in lean mass percentage is suggestive of worsening of health related outcomes.	0, 26, 52 weeks
Secondary	Late-life function and disability instrument	Self-reported 32-item physical function measure consisting of function and life-task items that correlate with gait speed and lower-limb function. A 2-point difference is clinically significant. Range, (scaled score, 0-100). Higher scores indicate better performance and less limitation than lower scores.	0, 8, 16, 26, 52, 78
Secondary	Change in Pittsburgh Fatigability questionnaire	The 15-item Pittsburgh Fatigability Scale measures perceived fatigue of sedentary, social, lifestyle and physical activities (light-high intensity, 0-50 scale). Cutoff of =15 and =13 indicate higher physical and mental fatigue that may lead to reduced performance or restricted activity. Higher scores indicate greater perceived physical or mental fatigability. A reduction in the absolute change in score suggests improvements in fatigue.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Self-efficacy- exercise	The Self-Efficacy for Exercise Scale (range 0-90) is based on the Social Cognitive Theory (higher scores mean higher self-efficacy for initiating/maintaining exercise). A positive change in self-efficacy reflects better outcomes, and a negative change reflects worse outcomes.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Self-efficacy- nutrition	The 8-item Weight-Efficacy Lifestyle Short Form measures confidence in adopting and maintaining weight loss behaviors. A 15-point change was related to a 25% weight loss in bariatric surgery participants. Range (0-80). A positive change in self-efficacy reflects better outcomes, and a negative change reflects worse outcomes.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Self-efficacy- technology	A 10-item Likert scale (1-10) will measure daily Technology Self-Efficacy (higher score means higher self-efficacy). Range (0-100)	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Goal setting- exercise	Only conducted in the Behavioral arms. This is a Likert Scale question, where answers can range from 1-10, with higher scores indicating better goal setting abilities	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Goal setting- nutrition	Only conducted in the Behavioral arms. This is a Likert Scale questionnaire, where answers can range from 1-10, with higher scores indicating better goal setting abilities.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in Goal setting- technology	Only conducted in the Behavioral arms. This is a Likert Scale questionnaire, where answers can range from 1-10, with higher scores indicating better goal setting abilities.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in social support for diet	A validated scale that assesses friends/family support for engaging in dietary changes. Higher scores indicate higher social support. Each are scored for family and friends separately (range 0-100).	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in social support for exercise	A validated scale that assesses friends/family support for engaging in dietary exercises. Higher scores indicate higher social support. Each are scored for family and friends separately (range 0-60).	0, 8, 16, 26, 52, 78 weeks
Secondary	Treatment self-regulation: diet	A validated 15-item, 7-point scale (range 0-100) reflecting autonomous motivation and controlled motivation. Higher scores indicate better outcomes.	0, 8, 16, 26, 52, 78 weeks
Secondary	Treatment self-regulation: exercise	A validated 15-item, 7-point scale (range 0-100) reflecting autonomous motivation and controlled motivation. Higher scores indicate better outcomes.	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in caloric intake	Using the Automated Self-Administered 24-hour Dietary Assessment (ASA-24), the investigators will measure caloric intake per day. Change measured in the difference between calories per day at baseline, throughout study, and follow-up assessment. This is an automated food recall that assess caloric intake. A change in caloric intake will be reported in kcal per day. Reduction in caloric input suggests reduced calorie intake.	0, 8, 16, 26, 52, 78 weeks
Secondary	Physical activity: community healthy activities model program for seniors	This questionnaire, known as CHAMPS (community healthy activities model program for seniors), will assess activity levels and types (weekly caloric expenditure; frequency of activities) and their changes. The investigators will use a standardized algorithm to assess low, moderate, vigorous activity and caloric output	0, 8, 16, 26, 52, 78 weeks
Secondary	Patient activation measure	Patient Activation Measure assesses knowledge, skills & confidence for managing health revealing insights into motivators, behaviors, attitudes & outcomes (4 points each; score 0-100, low to high) 0, 8, 16, 26, 52, 78 weeks	0, 8, 16, 26, 52, 78 weeks
Secondary	Fitbit use- Wear/non-wear time	Measurement using Fitbit data of the time spent during the day wearing the device.	0, 8, 16, 26, 52, 78 weeks
Secondary	Fitbit use- activity/steps	Evaluation using Fitbit data of the average number of steps (and total number to that point) a participant has engaged in	0, 8, 16, 26, 52, 78 weeks
Secondary	Attendance	Feasibility of study procedures measured as the mean attendance rate of all participants. Participant attendance rate = (total # of visits attended / total # of visits scheduled) x 100. There are no cut-off scores for interpretation. Higher scores indicate higher feasibility	78 weeks
Secondary	Acceptability of Study Intervention	Measured through an end of study satisfaction survey, acceptability is measured on a 10 point Likert scale conducted on all participants at 78-weeks. This is rated on a 1 (strongly disagree) to 10 (strongly agree) survey.	78 weeks
Secondary	Percent of participants rating the intervention as acceptable	Conducted on all participants using a 1-5 Likert scale to assess appropriateness of the study intervention measures using the following: completely disagree, disagree, neither agree or disagree, agree, completely agree. Acceptability is reported as Agree or Completely Agree responses. Percent is calculated as total number of participants rating as agree or complete agree divided by the number of total participants.	78 weeks
Secondary	Telehealth satisfaction	A end-of-study questionnaire that assesses patient satisfaction regarding the use of Telehealth (Likert scale, 1-10). Range 0-100. Higher scores indicate better outcomes.	52, 78 weeks
Secondary	Telehealth usability survey	A single item Likert scale (1-10) will measure usefulness, ease of use, effectiveness, reliability & satisfaction of telemedicine. This will be measured at the conclusion of the study intervention. Range 0-100. Higher scores indicate better outcomes.	52 weeks
Secondary	Change in systolic blood pressure	The difference between baseline and follow-up values-measured in mmHg (millimeters of mercury)- a value of 5mmHg (millimeters of mercury) is clinically significant	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in diastolic blood pressure	The difference between baseline and follow-up values (measured in mmHg)- a value of 5mmHg (millimeters of mercury) is clinically significant	0, 8, 16, 26, 52, 78 weeks
Secondary	Change in low density lipoprotein blood levels	The difference between baseline and follow-up values measured in mg/dL (milligrams per deciliter) using a lipid panel. Levels >100mg/dL would be potentially clinically actionable.; 0, 8, 52 weeks	0, 8, 52 weeks
Secondary	Change in high density lipoprotein blood levels	The difference between baseline and follow-up values measured in mg/dL (milligrams per deciliter) using a lipid panel	0, 8, 52 weeks
Secondary	Change in total cholesterol blood levels	The difference between baseline and follow-up values measured in mg/dL (milligrams per deciliter) using a lipid panel	0, 8, 52 weeks
Secondary	Change in glucose blood levels	The difference between baseline and follow-up values, units in mg/dL (milligrams per deciliter). A glucose level >126mg/dL is considered diabetic.	0, 8, 52 weeks
Secondary	Change in calf circumference from baseline	Change in calf circumference in centimeters (cm) over time from baseline to 12-weeks. Calf circumference will be measured objectively using a tape measure. A negative number will indicate a loss in calf circumference	8, 16, 26, 52, 78 weeks
Secondary	Change in arm circumference from baseline	Change in arm circumference in centimeters (cm) over time from baseline to 12-weeks. Arm circumference will be measured objectively using a tape measure. A negative number will indicate a loss in arm circumference.	8, 16, 26, 52, 78 weeks